Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Single-Shot Interscalene Blocks for Rebound Pain in Total Shoulder Arthroplasty
NCT07770165Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Randomised trial of ropivacaine (2 arms), sponsored by University of Calgary. Primary endpoint: Incidence of Rebound pain at 96 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ropivacaine
Beyond the preview
Go deeper on NCT07770165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770165.